

**K-161-2.01US**

A Phase 2, Prospective, Double-Masked, Randomized, Multi-Center, Vehicle-Controlled, Parallel-group, 4-week Administration Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in non-Japanese and Japanese Adult Subjects with Moderate to Severe Dry Eye Disease Both in Environmental and Controlled Adverse Environmental (CAE<sup>®</sup>) Settings

NCT #: 04084483

Clinical Trial Protocol

Amendment 1

13 June 2019

## Clinical Trial Protocol: K-161-2.01US

**Protocol Title:** A Phase 2, Prospective, Double-Masked, Randomized, Multi-Center, Vehicle-Controlled, Parallel-group, 4-week Administration Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in non-Japanese and Japanese Adult Subjects with Moderate to Severe Dry Eye Disease Both in Environmental and Controlled Adverse Environmental (CAE<sup>®</sup>) Settings

**Protocol Number:** K-161-2.01US / [REDACTED]

**Study Phase:** 2

**Investigational Product Name:** K-161

**IND/IDE/PMA Number:** 138738

**Indication:** Dry eye disease

**Investigators:** Multi-Center

**Sponsor:** Kowa Research Institute, Inc. (KRI)

Date

---

**Original Protocol:** 14 September 2018

---

**Amendment 1:** 13 June 2019

### Confidentiality Statement

This protocol contains confidential, proprietary information of [REDACTED] and/or Kowa Research Institute, Inc. Further dissemination, distribution or copying of this protocol or its contents is strictly prohibited.


**SPONSOR PERSONNEL**



[REDACTED]



**MEDICAL MONITOR**



## SYNOPSIS

<b>Protocol Title:</b>	A Phase 2, Prospective, Double-Masked, Randomized, Multi-Center, Vehicle-Controlled, Parallel-group, 4-week Administration Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in non-Japanese and Japanese Adult Subjects with Moderate to Severe Dry Eye Disease Both in Environmental and Controlled Adverse Environmental (CAE) Settings
<b>Protocol Number:</b>	K-161-2.01US / [REDACTED]
<b>Investigational Product:</b>	1. K-161 Ophthalmic Solution 2. Placebo Ophthalmic Solution (Vehicle)
<b>Study Phase:</b>	2
<b>Objective(s):</b>	The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 compared to its vehicle from Day 1 (baseline) to Day 29 in non-Japanese and Japanese adult subjects with moderate to severe dry eye disease both in environmental and CAE settings.
<b>Overall Study Design:</b>	
<b>Structure:</b>	Prospective, double-masked, randomized, multi-center, vehicle-controlled, parallel-group study
<b>Duration:</b>	An individual subject's participation is estimated to be approximately 6 weeks (42 days) with a follow-up phone call.
<b>Controls:</b>	Placebo Ophthalmic Solution (Vehicle)
<b>Dosage/Dose Regimen/ Instillation/Application/Use:</b>	Subjects eligible to be randomized will receive one of the following treatments to be administered bilaterally for 28 days (from Visit 2 to Visit 5). 1) [REDACTED] K-161 Ophthalmic Solution; [REDACTED] [REDACTED] 2) [REDACTED] K-161 Ophthalmic Solution; [REDACTED] [REDACTED] 3) [REDACTED] K-161 Ophthalmic Solution; [REDACTED] [REDACTED] 4) Placebo Ophthalmic Solution (Vehicle); [REDACTED] [REDACTED] During a 14-day study run-in period (for the purpose of subject selection) prior to randomization, all subjects will receive Placebo


	Ophthalmic Solution (Vehicle) [REDACTED] [REDACTED]
<b>Summary of Visit Schedule:</b>	5 visits over the course of approximately 6 weeks with a follow-up phone call. <ul style="list-style-type: none"><li>• Visit 1 = Day <math>-14 \pm 2</math>, CAE Screening</li><li>• Visit 2 = Day 1, CAE Confirmation/ Baseline</li><li>• Visit 3 = Day <math>8 \pm 1</math></li><li>• Visit 4 = Day <math>15 \pm 2</math></li><li>• Visit 5 = Day <math>29 \pm 2</math></li><li>• Follow-up Phone Call = Day <math>36 \pm 2</math></li></ul>
<b>Measures Taken to Reduce Bias:</b>	This is a double-masked, randomized treatment assignment study.
<b>Study Population Characteristics:</b>	
<b>Number of Subjects:</b>	Approximately 600 subjects will be screened to enroll approximately 240 (60 per treatment arm*) subjects [REDACTED]
<b>Condition/Disease:</b>	Dry Eye Disease (DED)
<b>Inclusion Criteria:</b>	
Subjects who meet all of the following criteria will be eligible to participate in the study.	
<b>Subjects must:</b>	

1. Be at least 18 years of age at the time of informed consent visit
  2. Have a reported history of dry eye disease in both eyes [REDACTED]  
[REDACTED] and a history of eye drop use for dry eye symptoms [REDACTED]

### **Exclusion Criteria:**

Subjects who meet any of the following criteria will not be eligible to participate in the study.

## **Subjects must not:**



Evaluation Criteria:	
	<p><b><u>Primary Efficacy Endpoints:</u></b></p> <p>The primary efficacy endpoint (sign) is:</p> <ul style="list-style-type: none"><li>• Change in inferior corneal staining score from Day 1 (baseline) to Day 29 by comparing [REDACTED] K-161 [REDACTED] to its vehicle [REDACTED] in CAE setting</li></ul> <p>The primary efficacy endpoint (symptom) is:</p> <ul style="list-style-type: none"><li>• Change in Ora Calibra® ODS from Day 1 (baseline) to Day 29 by comparing [REDACTED] K-161 [REDACTED] to its vehicle [REDACTED] [REDACTED] in CAE setting</li></ul>
<b>Efficacy Measures and Endpoints:</b>	<p><b><u>Important Secondary Efficacy Endpoints:</u></b></p> <p>The important secondary efficacy endpoints are:</p> <ul style="list-style-type: none"><li>• Change in Schirmer's Test value (unanesthetized) from Day 1 (baseline) to Day 29 by comparing [REDACTED] K-161 [REDACTED] [REDACTED] to its vehicle [REDACTED] in environmental setting</li><li>• Change in TFBUT from Day 1 (baseline) to Day 29 by comparing [REDACTED] K-161 [REDACTED] to its vehicle [REDACTED] in CAE setting</li></ul> <p><b><u>Secondary Efficacy Endpoints:</u></b></p> <p>The secondary efficacy endpoints are comparisons of the following associated with taking the vehicle [REDACTED] and K-161 [REDACTED] (i.e., [REDACTED] K-161 [REDACTED] and [REDACTED] K-161 [REDACTED] for:</p> <ul style="list-style-type: none"><li>• Fluorescein staining by region: central, superior, inferior, temporal, nasal and corneal sum as assessed by the Ora Calibra® Corneal and Conjunctival Staining Scale</li><li>• Lissamine green staining by region: central, superior, inferior, temporal, nasal, and conjunctival sum as assessed by the Ora Calibra® Corneal and Conjunctival Staining Scale</li><li>• Conjunctival Redness as assessed by the Ora Calibra® Scale</li><li>• TFBUT</li></ul>

	<ul style="list-style-type: none"><li>• Tear Osmolarity</li><li>• Schirmer's Test (unanesthetized)</li><li>• Blink Rate</li><li>• Ora Calibra® Ocular Discomfort Scale</li><li>• Ora Calibra® Ocular Discomfort and 4-Symptom Questionnaire</li><li>• Visual Analog Scale (VAS)<ul style="list-style-type: none"><li>▪ Burning/ Stinging</li><li>▪ Itching</li><li>▪ Foreign Body Sensation</li><li>▪ Blurred Vision</li><li>▪ Eye Dryness</li><li>▪ Photophobia</li><li>▪ Pain</li></ul></li><li>• OSDI<sup>©</sup></li><li>• Daily diary</li></ul>
<b>Safety Measures:</b>	<ul style="list-style-type: none"><li>■ [REDACTED]</li><li>■ [REDACTED]</li><li>■ [REDACTED]</li><li>• Adverse event query</li><li>■ [REDACTED]</li><li>■ [REDACTED]</li><li>■ [REDACTED]</li></ul>

	<ul style="list-style-type: none"><li>• Maximum dose tolerability by comparing the [REDACTED] K-161 [REDACTED] arm to the [REDACTED] and [REDACTED] K-161 [REDACTED] arms</li></ul>
<b>Other:</b>	[REDACTED]
<b>Analysis Populations</b>	
	<ul style="list-style-type: none"><li>• <u>Intent-to-Treat Population</u> – The intent-to-treat (ITT) population includes all randomized subjects. The primary analysis will be performed on the ITT population. Subjects in the ITT population will be analyzed as randomized.</li><li>• <u>Per Protocol Population</u> – The per protocol (PP) population includes subjects in the ITT population who do not have significant protocol deviations and who complete the study. Protocol deviations will be assessed prior to database lock and unmasking. Subjects in the PP population will be analyzed as treated.</li><li>• <u>Safety Population</u> – The safety population includes all subjects who have received at least one dose of the investigational product. The safety population will be analyzed for all safety assessments. Subjects in the Safety population will be analyzed as treated.</li></ul>
<b>Sample Size</b>	
	This study is expected to enroll 240 subjects in a 1:1:1:1 ratio across four treatment arms, or 60 subjects per treatment arm. In addition, randomization will be stratified such that [REDACTED] will be randomized in each treatment arm.  The standard deviation for change from baseline in post-CAE inferior corneal fluorescein staining ranges between 0.68 and 0.81 units. Assuming a common standard deviation of 0.77, a sample size of 60 subjects per group will have approximately 90% power to detect a difference of 0.46 units between the active treatment group and the vehicle group using a two-sample t-test at a two-sided significance level of 0.05. Again, it is assumed that adjusting for baseline and site will further reduce variability and provide >90% power.  Likewise, the standard deviation for change from baseline scores in the post-CAE ODS at Day 29 is assumed a common standard deviation of 0.82, a sample size of 60 subjects per group will have approximately 90% power to detect a difference of 0.49 units between the active treatment group and the vehicle group using a two-sample t-test at a two-sided significance level of 0.05. It is assumed that adjusting for baseline and site will further reduce variability and provide >90% power.

Multiplicity Consideration:

Common factors for multiplicity are multiple arms and multiple endpoints.

1) Multiple arms

The primary treatment comparison will be between the █ K-161 █ treatment arm and the vehicle █ treatment arm. Other treatment comparisons will be considered secondary or exploratory.

2) Multiple endpoints

The primary and important secondary endpoints will be tested hierarchically to maintain the study-wise Type I error rate of 0.05. First, change from baseline in inferior corneal fluorescein staining will be tested at an alpha level of 0.05. The test for change from baseline scores in the ODS will be conducted at an alpha level of 0.05 only if the previous test demonstrates significance. The test for change from baseline in Schirmer's test will be conducted at an alpha level of 0.05 only if the previous test demonstrates significance. The test for change from baseline in TFBUT will be conducted at an alpha level of 0.05 only if the previous test demonstrates significance. All other secondary and exploratory endpoints and treatment comparisons will be considered exploratory.

The hierarchical testing order will be as follows:

Primary comparisons:

1. Comparison of the change from baseline in post-CAE inferior corneal staining at Day 29 (█ K-161 █ vs vehicle)
2. Comparison of the change from baseline in post-CAE ocular discomfort at Day 29 (█ K-161 █ vs vehicle)

Important Secondary comparisons:

3. Comparison of the change from baseline in pre-CAE Schirmer's test value at Day 29 (█ K-161 █ vs vehicle)
4. Comparison of the change from baseline in post-CAE TFBUT at Day 29 (█ K-161 █ vs vehicle)

Thus, the study-wise Type I error rate will be maintained at 0.05 by considering only one dose of K-161 as the primary treatment comparison and using a hierarchical testing procedure.

Primary Efficacy Analyses:

The primary comparisons of change from baseline in post-CAE inferior corneal staining and ocular discomfort between the █ K-161 █ group and the vehicle group at Day 29, will be performed using analysis of covariance (ANCOVA) models. The respective baseline post-CAE score will be included as a covariate in each model and site will be included as a fixed effect. Treatment by baseline and treatment by site interactions will be explored in separate models and, if significant, analyses will be performed by baseline stratification and/or site, respectively, to further examine significant interactions. The primary analyses will use the ITT population.

For the primary endpoints multiple imputation with a control-based pattern mixture model will be used.

#### Secondary Efficacy Analyses

Secondary and exploratory efficacy endpoints will be analyzed similarly to the primary analyses on the ITT population. Continuous and ordinal variables collected at each visit will be summarized descriptively (n, mean, standard deviation, median, minimum and maximum), and analyzed with ANCOVA models each K-161 [REDACTED] group to the vehicle group. All visit-based data will be analyzed by visit and for each timepoint, if applicable, as well as the change from baseline.

Data collected pre- and post-CAE will also be analyzed for the change from pre- to post-CAE within each visit. Data collected during the CAE will also be analyzed using repeated measures models including all of the time points from a CAE exposure. Daily subject diary symptom data will be analyzed using each weekly average score from the diaries, as well as using repeated measures models across the diary collection period.

For the two important secondary endpoints, other secondary, and exploratory endpoints, multiple imputation with a control-based pattern mixture model will be used.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

#### Safety Variables

Adverse events (AEs) will be coded using the MedDRA dictionary. Frequencies and percentages of subjects with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs causing premature discontinuation will be provided by treatment group. An AE is treatment emergent if it occurs or worsens after the first dose of study treatment. Furthermore, frequencies will be given of subjects with TEAEs by system organ class; by system organ class and preferred term; by system organ class, preferred term and maximal severity; by system organ class and preferred term for treatment-related TEAEs; and by system organ class, preferred term, and study day of onset. Separate summaries will be performed for ocular and non-ocular AEs.

[REDACTED]

[REDACTED]

[REDACTED]


[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



## TABLE OF CONTENTS

Clinical Trial Protocol: K-161-2.01US .....	1
SYNOPSIS.....	3
TABLE OF CONTENTS.....	14
LIST OF ABBREVIATIONS.....	18
1 INTRODUCTION .....	20
1.1 Drug Profile from Non-clincial Studies .....	20
2 STUDY OBJECTIVES.....	21
3 CLINICAL HYPOTHESES .....	21
4 OVERALL STUDY DESIGN.....	21
5 STUDY POPULATION .....	22
5.1 Number of Subjects (approximate) .....	22
5.2 Study Population Characteristics.....	22
5.3 Inclusion Criteria.....	22
5.4 Exclusion Criteria.....	24
5.5 Withdrawal Criteria (if applicable) .....	25
6 STUDY PARAMETERS.....	26
6.1 Efficacy Endpoints .....	26
6.1.1 Primary Efficacy Endpoints.....	26
6.1.2 Important Secondary Efficacy Endpoints .....	26
6.1.3 Secondary Efficacy Endpoints .....	26
6.1.4 Exploratory Efficacy Endpoints.....	27
6.2 Safety Measures .....	27
6.3 Other Measures.....	27
6.7 Clinical Laboratory Measurements .....	29
7 STUDY MATERIALS .....	29
7.1 Study Treatments.....	29
7.1.1 Masking.....	29
7.1.2 Description of and Justification for the Route of Administration, Dosage, Dosage Regimen, and Treatment Period .....	29
7.1.3 Instructions for Use and Administration.....	30

7.2	Labeling, Packaging, Storage, Accountability, and Return or Disposal of Investigational Product.....	30
7.2.1	Labeling/Packaging.....	30
7.2.2	Storage of Investigational Product.....	30
7.2.3	Accountability of Investigational Product .....	30
7.2.4	Return or Disposal of Investigational Product.....	31
7.3	Other Study Supplies.....	31
8	STUDY METHODS AND PROCEDURES .....	31
8.1	Subject Entry Procedures .....	31
8.1.1	Overview.....	31
8.1.2	Informed Consent.....	31
8.1.3	Washout Intervals .....	31
8.1.4	Procedures for Final Study Entry.....	31
8.1.5	Methods for Assignment to Treatment Groups: .....	31
8.2	Concurrent Therapies .....	32
8.2.1	Prohibited Medications/Treatments .....	32
8.2.2	Escape Medications .....	32
8.2.3	Special Diet or Activities .....	32
8.3	.....	.....
8.4	Schedule of Visits, Measurements and Dosing .....	41
8.4.1	Scheduled Visits.....	41
8.4.2	Unscheduled Visits .....	41
8.5	Compliance with Protocol .....	42
8.6	Subject Disposition.....	42
8.6.1	Completed Subjects .....	42
8.6.2	Discontinued Subjects.....	42
8.7	Study Termination.....	42
8.8	Study Duration .....	43

8.9	Monitoring and Quality Assurance .....	43
9	ADVERSE EVENTS.....	43
9.1	Adverse Event .....	43
9.1.1	Severity .....	44
9.1.2	Relationship to Investigational Product.....	44
9.1.3	Expectedness.....	45
9.2	Serious Adverse Events.....	45
9.3	Procedures for Reporting Serious Adverse Events .....	46
9.3.1	Reporting a Serious Unexpected Suspected Adverse Reaction .....	46
9.3.2	Reporting a Serious Adverse Event .....	46
9.4	Procedures for Unmasking (if applicable).....	47
9.5	Type and Duration of the Follow-up of Subjects after Adverse Events ..	47
10	STATISTICAL HYPOTHESES AND METHODS OF ANALYSES.....	48
10.1	Analysis Populations .....	48
10.2	Statistical Hypotheses.....	48
10.3	Sample Size .....	49
10.4	Statistical Analysis .....	49
10.4.1	General Considerations .....	49
10.4.2	Unit of Analysis .....	49
10.4.3	Missing Data .....	50
10.4.4	Multiplicity Consideration .....	50
10.4.5	Efficacy Analyses .....	51
10.4.6	Safety Variables .....	51
10.4.7	Exploratory Safety Analyses.....	52
10.4.11	Interim Analyses .....	52
11	COMPLIANCE WITH GOOD CLINICAL PRACTICES, ETHICAL CONSIDERATIONS, AND ADMINISTRATIVE ISSUES.....	53
11.1	Protection of Human Subjects .....	53
11.1.1	Subject Informed Consent.....	53
11.1.2	Institutional Review Board (IRB) Approval.....	53
11.2	Ethical Conduct of the Study.....	53
11.3	Subject Confidentiality.....	53

11.4 Documentation .....	54
11.4.1 Retention of Documentation .....	54
11.5 Recording of Data on Source Documents and Case Reports Forms (CRFs) .....	54
11.6 Publications .....	54
12 REFERENCES .....	55
13 APPENDICES .....	56
Appendix 1: Schedule of Visits and Measurements .....	56
Appendix 2: Examination Procedures, Tests, & Evaluations .....	58
Appendix 3: Protocol Amendment Summary .....	73
	
Appendix 5: Investigator's Signature .....	75

## LIST OF ABBREVIATIONS

AE	Adverse event
CAE	Controlled adverse environment
CFR	Code of Federal Regulations
CRF	Case report form
CRO	Contract research organization
DED	dry eye disease
eCRF	electronic case report form
FDA	Food and Drug Administration
GCP	Good Clinical Practice
GLP	Good Laboratory Practice
HIPAA	Health Insurance Portability and Accountability Act
IB	Investigator's brochure
ICF	informed consent form
ICH	International Conference on Harmonisation
IEC	Independent Ethics Committee
IND	Investigational New Drug Application
IP	Investigational product
IRB	Institutional Review Board
ITT	Intent to treat
IWRS	Interactive web response system
LASIK	Laser in situ keratomileusis
LOCF	Last observation carried forward

MedDRA	Medical Dictionary for Regulatory Activities
NCS	Not clinically significant
ODS	Ocular Discomfort Score
OSDI	Ocular Surface Disease Index
OTC	Over the counter
PK	Pharmacokinetic
PP	Per protocol
SAE	Serious adverse event
SOP	Standard operating procedure
TFBUT	Tear film break-up time
WHO	World Health Organization

## 1 INTRODUCTION

Dry eye disease (DED) is a multifactorial, progressive disorder of the ocular surface resulting from insufficient tear coverage of the surface of the eye in combination with ocular surface inflammation. Patients with DED often experience severe pain, visual impairment, tear film hyperosmolarity and instability, inflammation, and corneal wounding. While the prevalence of DED is difficult to report due to varying definitions and diagnostic criteria, the global prevalence of DED is estimated to be between 5% and 50%, and increases with age (Bron et al. 2017). In the United States, it is estimated that as many as 3.2 million women and 1.7 million men over the age of 50 have DED, with a projected 40% increase in number of patients affected by 2030 (Schaumberg et al. 2002, Schaumberg et al. 2003, Schaumberg et al. 2009).

Current treatment and management of DED consists primarily of tear supplementation with lubricants (artificial tears). While artificial tears improve symptoms associated with DED, they have no effect on resolving the underlying conditions that lead to inflammation of the ocular surface. Three currently available options for treating inflammation at the ocular surface are Restasis® (cyclosporine ophthalmic emulsion) CEQUA™ (cyclosporine ophthalmic solution), and Xiidra® (lifitegrast ophthalmic solution). It has been shown that only 15% of patients respond to Restasis® after 6 months of treatment, as measured by Schirmer's test, and many more report ocular side-effects such as burning and stinging (Mah et al. 2012). Xiidra® has also been shown to be associated with ocular adverse events (AEs); in a clinical study of Xiidra® for subjects with DED, subjects reported increased ocular irritation upon instillation with Xiidra® compared to placebo (7.8% compared to 1.4% in the placebo group) (Tauber et al. 2015). Similarly, common adverse reactions reported after use of CEQUA include instillation site pain and conjunctival hyperemia (CEQUA 2018). Thus, there remains a medical need for more efficacious treatment options with a more favorable safety and comfort profile for patients with DED.

### 1.1 Drug Profile from Non-clinical Studies

[REDACTED] a tyrosine kinase involved in cytokine signaling and activation of lymphocytes. [REDACTED] have been shown to have potent anti-inflammatory activity both *in vitro* and *in vivo* ([REDACTED] [REDACTED]). [REDACTED] was shown to suppress ocular surface inflammation and corneal injury in a mouse model of dry eye disease ([REDACTED]). Because inflammation is a key component of DED, targeting the inflammatory pathway via [REDACTED] to reduce cytokine production and/or immune cell infiltration at the ocular surface may reduce the signs and symptoms of DED.

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

This will be the first clinical study of K-161 Ophthalmic Solution.

## 2 STUDY OBJECTIVES

Prior to any changes in a subject's medical treatment and/or study visit procedures, the study will be discussed with each subject and subjects wishing to participate must give written informed consent (and/or assent) and sign a Health Insurance Portability and Accountability Act (HIPAA) form.

The objectives of the study are to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 compared to its vehicle from Day 1 (baseline) to Day 29 in non-Japanese and Japanese adult subjects with moderate to severe dry eye disease both in environmental and Controlled Adverse Environment (CAE) settings.

## 3 CLINICAL HYPOTHESES

The clinical hypotheses for this study is that [REDACTED] K-161 Ophthalmic Solution [REDACTED] [REDACTED] ( [REDACTED] is superior to its vehicle ( [REDACTED] for the primary endpoints of signs and symptoms of dry eye, as follows:

- Sign: Post-CAE inferior corneal fluorescein staining score on the Ora Calibra® scale, measured by mean change from baseline (Visit 2) to Visit 5
- Symptom: Post-CAE ocular discomfort scale on the Ora Calibra® scale, measured by mean change from baseline (Visit 2) to Visit 5

## 4 OVERALL STUDY DESIGN

This is a Phase 2, multicenter, randomized, double-masked, vehicle-controlled, parallel-group design with block enrollment. Subjects will be randomized to one of the following treatment groups at Visit 2:

- [REDACTED] K-161; [REDACTED] ( [REDACTED] (N=~60)
- [REDACTED] K-161; [REDACTED] ( [REDACTED] (N=~60)
- [REDACTED] K-161; [REDACTED] ( [REDACTED] (N=~60)
- Placebo Ophthalmic Solution (Vehicle); [REDACTED] ( [REDACTED] (N=~60)

Approximately 240 subjects will be randomly assigned to one of the four treatment groups (1:1:1:1). [REDACTED]

[REDACTED] Subjects, Sponsor, Contract research organization (CRO), and site personnel will be masked to treatment assignment. To ensure masking, a dedicated unmasked staff member/technician will be delegated to dispense and observe instillation of randomized study drug and collect randomized study drug from a subject for drug accountability. The unmasked staff member will also collect and review the subject's daily dosing diary. This person cannot perform any other study-related procedures. Additionally, the informed consent form (ICF) will not indicate any relationship between dosing regimen and treatment. Subjects will be instructed not to discuss their assigned dosing regimen or perceived treatment effects with other study participants.

During the screening period, two 90-minute exposures to the CAE will be conducted to ascertain eligibility to enter the study. Subjects who qualify after the initial screening visit will enter the run-in phase, where they will self-administer vehicle [REDACTED] for approximately 14 days. Those who qualify at Visit 2 (Day 1) will be randomized to receive study drug in a double-masked fashion for 28 days.

Randomization will be stratified on Visit 2 Post-CAE inferior fluorescein staining and Post-CAE ocular discomfort on the Ora Calibra® scale. Subjects will self-administer drops either [REDACTED] or [REDACTED] and will complete daily diary assessments as instructed.

At Visit 4 (Day 15) and Visit 5 (Day 29), CAE exposure will occur, with pre-CAE, during CAE (symptoms only) and post-CAE assessments of ocular signs and symptoms. At Visit 3, no CAE exposure will occur but signs and symptoms will be assessed. Study drug will be discontinued at Visit 5. Subjects will exit from the study at this visit. The follow-up phone call will occur about 7 days after the final day of randomized study drug treatment.

The timing of subject visits and examinations will be consistent throughout the study.

## 5 STUDY POPULATION

### 5.1 Number of Subjects (approximate)

It is estimated that approximately 600 subjects will be screened to enroll approximately 240 randomized subjects (60 in each group). [REDACTED]

[REDACTED] Subjects will be randomized in a 1:1:1:1 ratio of

- [REDACTED] K-161; [REDACTED]
- [REDACTED] K-161; [REDACTED]
- [REDACTED] K-161; [REDACTED]
- Placebo Ophthalmic Solution (Vehicle); [REDACTED]

### 5.2 Study Population Characteristics

All subjects must be at least 18 years of age, of either gender, and of any race, and must meet all inclusion criteria and none of the exclusion criteria.

### 5.3 Inclusion Criteria



#### Each subject must:




1. Be at least 18 years of age at the time of informed consent visit
2. Have a reported history of dry eye disease in both eyes [REDACTED]  
[REDACTED] and have a history of eye drop use for dry eye symptoms  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]



## 5.4 Exclusion Criteria

### Each subject must not:

1. Have any clinically significant ocular condition   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  2. Have a history of   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  


## 5.5 Withdrawal Criteria (if applicable)

If at any time during the study the investigator determines that a subject's safety has been compromised, the subject may be withdrawn from the study.

Subjects may withdraw consent from the study at any time.

Sponsor and/or investigator may discontinue any subject for non-compliance or any valid medical reason (see Section 8.6.2).

The subject has the right to withdraw from the study at any time. Nevertheless, in this study, every attempt will be made to prevent missing data and to obtain complete follow up of all subjects during the study period. Investigators will be trained to minimize full withdrawals from the study period wherever possible. Subjects who discontinue study drug during the study period are not required to withdraw from the study. These subjects will be encouraged to remain in the study and asked to conduct the remaining study visits as outlined in the protocol through Visit 5. If a subject fails to actively maintain contact with the Investigator, reasonable efforts (telephone calls to family members or friends, e-mail contacts, etc.) will be made in order to encourage the subject to complete the study visits.

## 6 STUDY PARAMETERS

### 6.1 Efficacy Endpoints

#### 6.1.1 Primary Efficacy Endpoints

The primary efficacy endpoint (sign) is:

- Change in inferior corneal staining score from Day 1 (baseline) to Day 29 by comparing [REDACTED] K-161 [REDACTED] to its vehicle [REDACTED] in CAE setting

The primary efficacy endpoint (symptom) is:

- Change in Ora Calibra® ODS from Day 1 (baseline) to Day 29 by comparing [REDACTED] K-161 [REDACTED] to its vehicle [REDACTED] in CAE setting

#### 6.1.2 Important Secondary Efficacy Endpoints

The important secondary endpoints are:

- Change in Schirmer's Test value (unanesthetized) from Day 1 (baseline) to Day 29 by comparing [REDACTED] K-161 [REDACTED] to its vehicle [REDACTED] in environmental setting
- Change in TFBUT from Day 1 (baseline) to Day 29 by comparing [REDACTED] K-161 [REDACTED] to its vehicle [REDACTED] in CAE setting

#### 6.1.3 Secondary Efficacy Endpoints

The secondary efficacy endpoints are comparisons of the following associated with taking the vehicle [REDACTED] and K-161 [REDACTED] (i.e., [REDACTED] K-161 [REDACTED] and [REDACTED] K-161 [REDACTED] for:

- Fluorescein staining by region: central, superior, inferior, temporal, nasal and corneal sum as assessed by the Ora Calibra® Corneal and Conjunctival Staining Scale
- Lissamine green staining by region: central, superior, inferior, temporal, nasal, and conjunctival sum as assessed by the Ora Calibra® Corneal and Conjunctival Staining Scale
- Conjunctival Redness as assessed by the Ora Calibra® Scale
- TFBUT
- Tear Osmolarity
- Schirmer's Test (unanesthetized)
- Blink Rate
- Ora Calibra® Ocular Discomfort Scale
- Ora Calibra® Ocular Discomfort and 4-Symptom Questionnaire
- Visual Analog Scale (VAS)
  - Burning/ Stinging
  - Itching
  - Foreign Body Sensation

- Blurred Vision
  - Eye Dryness
  - Photophobia
  - Pain
  - OSDI<sup>©</sup>
  - Daily diary

## 6.1.4

- | Term                    | Percentage |
|-------------------------|------------|
| Climate change          | 92%        |
| Global warming          | 98%        |
| Green energy            | 95%        |
| Carbon footprint        | 95%        |
| Sustainable development | 98%        |
| Renewable energy        | 96%        |
| Emissions reduction     | 93%        |
| Green economy           | 97%        |
| Carbon tax              | 94%        |

## 6.2 Safety Measures

The safety measures being evaluated are:

- AE query
  - Maximum dose tolerability by comparing the █ K-161 █ arm to the █ and █ K-161 █ arms

### 6.3 Other Measures

The other measures being evaluated are:

- | Term                    | Percentage |
|-------------------------|------------|
| Climate change          | 95         |
| Global warming          | 92         |
| Green energy            | 88         |
| Carbon footprint        | 85         |
| Sustainable development | 82         |
| Renewable energy        | 78         |
| Emissions reduction     | 75         |
| Green economy           | 72         |
| Carbon tax              | 68         |

## 6.4

- Confidential

6.5

Term	Percentage
GMOs	85%
Organic	92%
Natural	88%
Artificial	65%
Organic	90%
Natural	87%
Artificial	72%
Organic	89%
Natural	86%
Artificial	71%
Organic	88%
Natural	85%
Artificial	68%
Organic	87%
Natural	84%
Artificial	67%
Organic	86%
Natural	83%
Artificial	66%
Organic	85%
Natural	82%
Artificial	65%
Organic	84%
Natural	81%
Artificial	64%
Organic	83%
Natural	80%
Artificial	63%
Organic	82%
Natural	79%
Artificial	62%
Organic	81%
Natural	78%
Artificial	61%
Organic	80%
Natural	77%
Artificial	60%
Organic	79%
Natural	76%
Artificial	59%
Organic	78%
Natural	75%
Artificial	58%
Organic	77%
Natural	74%
Artificial	57%
Organic	76%
Natural	73%
Artificial	56%
Organic	75%
Natural	72%
Artificial	55%
Organic	74%
Natural	71%
Artificial	54%
Organic	73%
Natural	70%
Artificial	53%
Organic	72%
Natural	69%
Artificial	52%
Organic	71%
Natural	68%
Artificial	51%
Organic	70%
Natural	67%
Artificial	50%
Organic	69%
Natural	66%
Artificial	49%
Organic	68%
Natural	65%
Artificial	48%
Organic	67%
Natural	64%
Artificial	47%
Organic	66%
Natural	63%
Artificial	46%
Organic	65%
Natural	62%
Artificial	45%
Organic	64%
Natural	61%
Artificial	44%
Organic	63%
Natural	60%
Artificial	43%
Organic	62%
Natural	59%
Artificial	42%
Organic	61%
Natural	58%
Artificial	41%
Organic	60%
Natural	57%
Artificial	40%
Organic	59%
Natural	56%
Artificial	39%
Organic	58%
Natural	55%
Artificial	38%
Organic	57%
Natural	54%
Artificial	37%
Organic	56%
Natural	53%
Artificial	36%
Organic	55%
Natural	52%
Artificial	35%
Organic	54%
Natural	51%
Artificial	34%
Organic	53%
Natural	50%
Artificial	33%
Organic	52%
Natural	49%
Artificial	32%
Organic	51%
Natural	48%
Artificial	31%
Organic	50%
Natural	47%
Artificial	30%
Organic	49%
Natural	46%
Artificial	29%
Organic	48%
Natural	45%
Artificial	28%
Organic	47%
Natural	44%
Artificial	27%
Organic	46%
Natural	43%
Artificial	26%
Organic	45%
Natural	42%
Artificial	25%
Organic	44%
Natural	41%
Artificial	24%
Organic	43%
Natural	40%
Artificial	23%
Organic	42%
Natural	39%
Artificial	22%
Organic	41%
Natural	38%
Artificial	21%
Organic	40%
Natural	37%
Artificial	20%
Organic	39%
Natural	36%
Artificial	19%
Organic	38%
Natural	35%
Artificial	18%
Organic	37%
Natural	34%
Artificial	17%
Organic	36%
Natural	33%
Artificial	16%
Organic	35%
Natural	32%
Artificial	15%
Organic	34%
Natural	31%
Artificial	14%
Organic	33%
Natural	30%
Artificial	13%
Organic	32%
Natural	29%
Artificial	12%
Organic	31%
Natural	28%
Artificial	11%
Organic	30%
Natural	27%
Artificial	10%
Organic	29%
Natural	26%
Artificial	9%
Organic	28%
Natural	25%
Artificial	8%
Organic	27%
Natural	24%
Artificial	7%
Organic	26%
Natural	23%
Artificial	6%
Organic	25%
Natural	22%
Artificial	5%
Organic	24%
Natural	21%
Artificial	4%
Organic	23%
Natural	20%
Artificial	3%
Organic	22%
Natural	19%
Artificial	2%
Organic	21%
Natural	18%
Artificial	1%
Organic	20%
Natural	17%
Artificial	0%

6.6

This horizontal bar chart displays the distribution of 100 data points across 100 categories. The categories are represented by horizontal black bars of varying lengths. Category 1 has the longest bar, followed by Category 2. Category 3 has a very short bar. Category 4 has a medium-length bar. Category 5 has a long bar. Category 6 has a very short bar. Category 7 has a medium-length bar. Category 8 has a long bar. Category 9 has a very short bar. Category 10 has a medium-length bar. Category 11 has a long bar. Category 12 has a very short bar. Category 13 has a medium-length bar. Category 14 has a long bar. Category 15 has a very short bar. Category 16 has a medium-length bar. Category 17 has a long bar. Category 18 has a very short bar. Category 19 has a medium-length bar. Category 20 has a long bar. Category 21 has a very short bar. Category 22 has a medium-length bar. Category 23 has a long bar. Category 24 has a very short bar. Category 25 has a medium-length bar. Category 26 has a long bar. Category 27 has a very short bar. Category 28 has a medium-length bar. Category 29 has a long bar. Category 30 has a very short bar. Category 31 has a medium-length bar. Category 32 has a long bar. Category 33 has a very short bar. Category 34 has a medium-length bar. Category 35 has a long bar. Category 36 has a very short bar. Category 37 has a medium-length bar. Category 38 has a long bar. Category 39 has a very short bar. Category 40 has a medium-length bar. Category 41 has a long bar. Category 42 has a very short bar. Category 43 has a medium-length bar. Category 44 has a long bar. Category 45 has a very short bar. Category 46 has a medium-length bar. Category 47 has a long bar. Category 48 has a very short bar. Category 49 has a medium-length bar. Category 50 has a long bar. Category 51 has a very short bar. Category 52 has a medium-length bar. Category 53 has a long bar. Category 54 has a very short bar. Category 55 has a medium-length bar. Category 56 has a long bar. Category 57 has a very short bar. Category 58 has a medium-length bar. Category 59 has a long bar. Category 60 has a very short bar. Category 61 has a medium-length bar. Category 62 has a long bar. Category 63 has a very short bar. Category 64 has a medium-length bar. Category 65 has a long bar. Category 66 has a very short bar. Category 67 has a medium-length bar. Category 68 has a long bar. Category 69 has a very short bar. Category 70 has a medium-length bar. Category 71 has a long bar. Category 72 has a very short bar. Category 73 has a medium-length bar. Category 74 has a long bar. Category 75 has a very short bar. Category 76 has a medium-length bar. Category 77 has a long bar. Category 78 has a very short bar. Category 79 has a medium-length bar. Category 80 has a long bar. Category 81 has a very short bar. Category 82 has a medium-length bar. Category 83 has a long bar. Category 84 has a very short bar. Category 85 has a medium-length bar. Category 86 has a long bar. Category 87 has a very short bar. Category 88 has a medium-length bar. Category 89 has a long bar. Category 90 has a very short bar. Category 91 has a medium-length bar. Category 92 has a long bar. Category 93 has a very short bar. Category 94 has a medium-length bar. Category 95 has a long bar. Category 96 has a very short bar. Category 97 has a medium-length bar. Category 98 has a long bar. Category 99 has a very short bar. Category 100 has a medium-length bar.

A horizontal bar chart with eight categories on the x-axis and a single data series represented by black bars. The categories are: '1-2', '3-4', '5-6', '7-8', '9-10', '11-12', '13-14', and '15-16'. The length of each bar corresponds to the number of countries in that category. The bars are ordered from longest to shortest: '1-2', '13-14', '15-16', '7-8', '3-4', '11-12', '9-10', and '5-6'.

Category	Number of Countries
1-2	10
3-4	6
5-6	2
7-8	5
9-10	3
11-12	4
13-14	8
15-16	7

## 6.7 Clinical Laboratory Measurements

The following assessments are being conducted:

## Hematology:

## Clinical chemistry:

## Urinalysis:

## 7 STUDY MATERIALS

## 7.1 Study Treatments

### 7.1.1 Masking

All arms will be double-masked. To ensure masking, an unmasked technician delegated by the Investigator will perform all study drug instruction, dispensation, collection and accountability. This technician cannot perform any other study visit procedures. Study Treatments/Formulations

- [REDACTED] K-161; [REDACTED]
  - [REDACTED] K-161; [REDACTED]
  - [REDACTED] K-161; [REDACTED]
  - Placebo Ophthalmic Solution (Vehicle); [REDACTED]

**7.1.2 Description of and Justification for the Route of Administration, Dosage, Dosage Regimen, and Treatment Period.**

Topical ophthalmic dosing is the optimal route of administration for dry eye treatments. The dosage and dosage regimen were selected based on non-clinical studies. The proposed treatment period of 4 weeks is based on results from pre-clinical studies and on the anti-inflammatory mechanism of action of the drug.

### **7.1.3 Instructions for Use and Administration**

Subjects who were randomized to █ arm must administer study drug █  
Subjects who were randomized to █ arm must █  
█ If missed, the subject must not administer the eye drop if the next dosing is in less than 2 hours. At Visits 2, 3, 4, and 5, all subjects must visit their study sites without administering any topical ophthalmic preparations, including study drug, and must not administer topical ophthalmic preparations until all examinations are finished.

Subjects, Sponsor, CRO, and site personnel (with the exception of the following person) will be masked to treatment assignment. To ensure masking, a dedicated unmasked staff member/technician will be delegated to dispense and observe instillation of randomized study drug and collect randomized study drug from a subject for drug accountability. This person cannot perform any other study-related procedures. Additionally, the ICF will not indicate any relationship between dosing regimen and treatment. Subjects will be instructed not to discuss their assigned dosing regimen or any perceived treatment effects with other study participants.

## **7.2 Labeling, Packaging, Storage, Accountability, and Return or Disposal of Investigational Product**

### **7.2.1 Labeling/Packaging**

Investigational product (IP) will be packaged and labeled into clinical kits.

#### Run-in Period

For the run-in period, █ provide a sufficient medication supply.

#### Treatment Period

█ **Dosing:** For the treatment period, █ provide a sufficient supply of randomized study drug.

█ **Dosing:** For the treatment period, █ provide a sufficient supply of randomized study drug.

### **7.2.2 Storage of Investigational Product**

The IPs must be stored in a secure area accessible only to the investigator and his/her designees. K-161 must be stored at controlled room temperature of 20-25°C (68-77°F) with excursions permitted between 15°C and 30°C (59-86°F), as indicated on the product label.

### **7.2.3 Accountability of Investigational Product**

The IP is to only be prescribed by the PI or his/her named Sub-Investigator(s), and is to only be used in accordance with this protocol. The IP must only be distributed to subjects properly qualified as described in this protocol to receive IP.

The investigator must keep an accurate accounting of the IP received from the supplier. This includes the amount of IP dispensed to subjects, amount of IP returned to the investigator by the subjects, and the amount returned or disposed upon the completion of the study. A detailed inventory must be completed for the IP. Study drug accountability will be performed by an Unmasked Technician as delegated by the PI. To ensure masking, a dedicated unmasked staff member/technician will be delegated to dispense and collect randomized study drug from a subject for drug accountability. This person cannot perform any other study-related procedures.

#### **7.2.4 Return or Disposal of Investigational Product**

All IP (used or unused) will be returned to the Sponsor or their designee. Requests for the return of IP must be specified in writing.

### **7.3 Other Study Supplies**

Other study supplies include [REDACTED] Schirmer's test strips, tear meniscometry strips, sodium fluorescein, lissamine green, [REDACTED] tear osmolarity cards, [REDACTED]  
[REDACTED]

## **8 STUDY METHODS AND PROCEDURES**

### **8.1 Subject Entry Procedures**

#### **8.1.1 Overview**

Subjects as defined by the criteria in sections 5.2 and 5.3 will be considered for entry into this study.

#### **8.1.2 Informed Consent**

Prior to a subject's participation in the study (i.e., changes in a subject's medical treatment and/or study related procedures), the study will be discussed with each subject, and subjects wishing to participate must give written informed consent using an ICF. The ICF must be the most recent version that has received approval/favorable review by a properly constituted Institutional Review Board (IRB).

#### **8.1.3 Washout Intervals**

Prohibited medications, treatments, and activities are outlined in the exclusion criteria (Section [5.4](#)).

#### **8.1.4 Procedures for Final Study Entry**

Subjects must meet all inclusion and none of the exclusion criteria (Section [5.3](#) and [5.4](#)).

#### **8.1.5 Methods for Assignment to Treatment Groups:**

Before the initiation of study run-in at Visit 1, each subject who provides written informed consent will be assigned a screening number. All screening numbers will be assigned in strict numerical sequence at a site and no numbers will be skipped or omitted. Each subject who meets all the inclusion and none of the exclusion criteria at Visit 1 and Visit 2 will be assigned a randomization number at the end of Visit 2. The Interactive Web Response System (IWRS) will be used to assign all randomization numbers.

For the non-Japanese subjects, randomization will be further stratified by the following factors and cut-offs:

Randomization and kit numbers will be assigned automatically to each subject as they are entered into the IWRs.

The site staff will dispense kit(s) required until the next visit. Both the randomization number and the dispensed study drug kit number(s) will be recorded on the subject's source document and electronic case report form (eCRF). Subjects, Sponsor, CRO, and site personnel will be masked to treatment assignment. To ensure masking, a dedicated unmasked staff member/technician will be delegated to dispense and observe instillation of randomized study drug and collect randomized study drug from a subject for drug accountability. This person cannot perform any other study-related procedures.

## 8.2 Concurrent Therapies

The use of any concurrent medication, prescription or OTC, is to be recorded on the subject's source document and corresponding eCRF along with the reason the medication was taken.

Concurrent enrollment in another investigational drug or medical device study is not permitted.

### 8.2.1 Prohibited Medications/Treatments

Disallowed medications/treatments during the study are outlined in the Exclusion Criteria (Section 5.4).

### 8.2.2 Escape Medications

No escape medications are required for this study.

### 8.2.3 Special Diet or Activities

No special diets or activities are required for this study.

### 8.3 Examination Procedures

### **8.3.1 Procedures to be Performed at Each Study Visit with Regard to Study Objectives**

Procedures listed below should be performed in the given order. See [Appendix 1](#) for the Schedule of Visits and Measurements [Appendix 2](#) for details on methodologies and grading systems.

### 8.3.2 Visit 1: Day $-14 \pm 2$ – CAE Screening

All subjects will undergo the following screening assessments:

- Informed Consent/HIPAA
  - [REDACTED]
  - [REDACTED]
  - [REDACTED]
  - [REDACTED]
  - [REDACTED]
  - [REDACTED]
  - Ora Calibra® Ocular Discomfort Scale
  - Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire
  - OSDI® Questionnaire
  - Visual Analog Scale (VAS)
  - [REDACTED]
  - [REDACTED]
  - Conjunctival Redness
  - TFBUT
  - Fluorescein Staining
  - Lissamine Green Staining
  - At least 15-minute wait between lissamine green staining and Schirmer's test
  - Schirmer's test
  - [REDACTED]
  - [REDACTED]
  - [REDACTED]
  - [REDACTED]
  - Ora Calibra® Ocular Discomfort Scale
  - Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire
  - Visual Analog Scale (VAS)
  - [REDACTED]
  - Conjunctival Redness
  - TFBUT
  - Fluorescein Staining
  - Lissamine Green Staining

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

- Dispensation of run-in (Vehicle) for [REDACTED] dosing until Visit 2

○ [REDACTED]

[REDACTED]

■ [REDACTED]

- Ora Calibra® Drop Comfort Scale
- Ora Calibra® Drop Comfort Questionnaire
- Diary and Subject Instructions Dispensation

■ [REDACTED]

[REDACTED]

- AE Query
- Subjects will be scheduled for Visit 2.

### **8.3.3 Visit 2: Day 1 – CAE Confirmation and Baseline**

[REDACTED]

- Study Diary/Run-in Collection

■ [REDACTED]

- Medical/medication history update

- AE query

■ [REDACTED]

- Ora Calibra® Ocular Discomfort Scale

- Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire

- OSDI® Questionnaire

- Visual Analog Scale (VAS)

■ [REDACTED]

■ [REDACTED]

- Conjunctival Redness
- Blink Rate
- Tear Osmolarity

■ [REDACTED]

- TFBUT
- Fluorescein Staining
- Lissamine Green Staining
- At least 15-minute wait between lissamine green staining and Schirmer's test
- Schirmer's test

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]  
■ [REDACTED]

■ [REDACTED]

- Ora Calibra® Ocular Discomfort Scale
- Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire
- Visual Analog Scale (VAS)

■ [REDACTED]

■ [REDACTED]

- Conjunctival Redness
- TFBUT
- Fluorescein Staining
- Lissamine Green Staining

■ [REDACTED]


- Randomization
- Study Drug Kit Dispensation: All subjects having a positive response and meeting all other screening eligibility criteria at the end of Visit 2 will be randomized to one of four treatment groups utilizing the IWRS system. Subjects will receive their assigned study drug kit with sufficient supply to last until Visit 3.

■ [REDACTED]

■ [REDACTED]

- Ora Calibra® Drop Comfort Scale
- Ora Calibra® Drop Comfort Questionnaire

■ [REDACTED]



- AE Query
- Subjects will be scheduled for Visit 3.

#### **8.3.4 Visit 3: Day 8 ±1**

- Study Drug Diary/Study Drug Collection by unmasked staff member
- Medical/medication history update
- AE Query
- Ora Calibra® Ocular Discomfort Scale
- Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire
- OSDI® Questionnaire
- Visual Analog Scale (VAS)



- Conjunctival Redness
- Blink Rate
- Tear Osmolarity
- TFBUT
- Fluorescein Staining

- Lissamine Green Staining
  - At least 15-minute wait between lissamine green staining and Schirmer's test
  - Schirmer's Test
  - Study Drug Kit Dispensation: Prior to discharge from the study site on Visit 3, subjects will be assigned a new study drug kit via the IWRS system for at-home dosing up to Visit 4.
  - Diary and Subject Instructions Dispensation

Topic	Percentage
Climate change	100
Global warming	98
Green energy	95
Renewable energy	92
Sustainable development	88
Carbon footprint	85
Green economy	82
Environmental protection	78
Conservation	75
Green technology	72
Green products	68
Green living	65
Green lifestyle	62
Green products	58
Green technology	55
Green economy	52
Conservation	48
Environmental protection	45
Sustainable development	42
Green energy	38
Renewable energy	35
Global warming	32
Climate change	30

- AE Query
- Subjects will be scheduled for Visit 4.

### 8.3.5 Visit 4: Day 15 ± 2

- Study Drug Diary/Study Drug Collection by unmasked staff member
- Medical/medication history update
- AE query
- Ora Calibra® Ocular Discomfort Scale
- Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire
- OSDI® Questionnaire
- Visual Analog Scale (VAS)
- [REDACTED]
- [REDACTED]
- Conjunctival Redness
- Blink Rate
- Tear Osmolarity
- TFBUT
- Fluorescein Staining
- Lissamine Green Staining
- At least 15-minute wait between lissamine green staining and Schirmer's test
- Schirmer's Test
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

- Ora Calibra® Ocular Discomfort Scale
- Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire
- Visual Analog Scale (VAS)

- [REDACTED]
- Conjunctival Redness
- TFBUT
- Fluorescein Staining
- Lissamine Green Staining

- Study Drug Kit Dispensation: Prior to discharge from the study site on Visit 4, subjects will be assigned a new study drug kit via the IWRS system for at-home dosing up to Visit 5.
  - Diary and Subject Instructions Dispensation


Country	Percentage (%)
United States	28
United Kingdom	27
Germany	25
France	24
Italy	23
Spain	22
Australia	21
Canada	20
Sweden	19
Norway	18

- AE Query
  - Subjects will be scheduled for Visit 5.

### 8.3.6 Visit 5: Day 29 ± 2

1000

- Study Drug Diary/Study Drug Collection by unmasked staff member
  - Medical/medication history update
  - AE query

1 

- Ora Calibra® Ocular Discomfort Scale

- Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire
- OSDI® Questionnaire
- Visual Analog Scale (VAS)
- [REDACTED]
- [REDACTED]
- Conjunctival Redness
- Blink Rate
- Tear Osmolarity
- [REDACTED]
- TFBUT
- Fluorescein Staining
- Lissamine Green Staining
- At least 15-minute wait between lissamine green staining and Schirmer's test
- Schirmer's Test
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- Ora Calibra® Ocular Discomfort Scale
- Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire
- Visual Analog Scale (VAS)
- [REDACTED]
- [REDACTED]
- Conjunctival Redness
- TFBUT
- Fluorescein Staining
- Lissamine Green Staining
- [REDACTED]
- [REDACTED]
- [REDACTED]
- AE Query

### **8.3.7 Follow-up phone call Day 36 ± 2**

- Follow-up phone call (about 7 days after the final day of randomized study drug treatment)
- AE query
- Study exit

### **Early Termination/Discontinuation**

If a subject is discontinued from the study prior to Visit 5 (Day 29 ± 2), then all safety evaluations and [REDACTED] evaluations for Visit 5 (Day 29 ± 2) should be performed on the day of discontinuation (early termination) or at the discretion of the investigator.

AEs (both elicited and observed) and SAEs will be monitored throughout the study. The investigator will promptly review all AEs (both elicited and observed) for accuracy and completeness. All AEs will be documented on the appropriate source document and case report form.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

## **8.4 Schedule of Visits, Measurements and Dosing**

### **8.4.1 Scheduled Visits**

Refer to Appendix 1 for a schedule of visits and measurements.

### **8.4.2 Unscheduled Visits**

These visits may be performed in order to ensure subject safety. All procedures performed at an unscheduled visit will be recorded in the source documents and on the Unscheduled Visit eCRF pages. Any procedure indicated in the eCRF that is not performed should be indicated as “Not done.”

Evaluations that may be conducted at an Unscheduled Visit include:

- [REDACTED]
- Assessment of AEs
- [REDACTED]

## 8.5 Compliance with Protocol

Subjects will be given written instructions; instructed on proper use of the subject daily diary and proper instillation; and instructed on proper storage of the IP at the end of Visits 1, 2, 3, and 4. The subject daily diaries, used/unused [REDACTED] will be collected at each visit from Visit 2 up to and including Visit 5 to assess dosing and symptom assessment compliance. Dosing compliance will be based on [REDACTED] [REDACTED] If the subject is less than 80% or more than 125% compliant with dosing based on [REDACTED] then the subject will be deemed non-compliant and a dosing deviation should be recorded in the source document.

In the subject daily diary, if more than 20% of Dose boxes are checked “no”, left blank, or missing for a diary period, a subject will be deemed non-compliant and a diary deviation will be recorded in the source document. Subjects with more than 20% of the total diary symptom assessments missed for that dosing period will be deemed non-compliant, and a diary symptom assessment deviation will be recorded in the source document. The investigator will use these guidelines to determine subject study compliance and deviation compliance.

## 8.6 Subject Disposition

### 8.6.1 Completed Subjects

A completed subject is one who has not been discontinued from the study.

### 8.6.2 Discontinued Subjects

Subjects may be discontinued prior to their completion of the study due to:

- subject request/withdrawal
- AEs
- protocol violations
- administrative reasons (e.g., inability to continue, lost to follow up)
- sponsor termination of study
- other

Note: In addition, any subject may be discontinued for any sound medical reason.

Notification of a subject discontinuation and the reason for discontinuation will be reported to [REDACTED] and/or the Sponsor and clearly documented on the electronic case report form (eCRF).

## 8.7 Study Termination

The study may be stopped at any time by the investigator, Sponsor, and/or [REDACTED] with prior notification.

## **8.8 Study Duration**

An individual subject's participation will involve 5 visits over approximately a 6-week (~42 days) period (14 days pre-screening, 28 days of treatment) and a follow-up phone call.

## **8.9 Monitoring and Quality Assurance**

During the course of the study, an █ monitor, or designee, will make routine site visits to review protocol compliance, assess IP accountability, and ensure the study is being conducted according to the pertinent regulatory requirements. The review of the subjects' medical records will be performed in a manner that adequately maintains subject confidentiality. Further details of the study monitoring will be outlined in a monitoring plan.

Regulatory authorities of domestic and foreign agencies, quality assurance (QA) and or its designees may carry out on-site inspections and/or audits which may include source data checks. Therefore, direct access to the original source data will be required for inspections and/or audits. All inspections and audits will be carried out giving consideration to data protection as well as subject confidentiality to the extent that local, state, and federal laws apply.

# **9 ADVERSE EVENTS**

## **9.1 Adverse Event**

An AE is defined as any untoward medical occurrence associated with the use of an IP in humans, whether or not considered IP-related. An AE can be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IP, without any judgment about causality. An AE can arise from any use of the IP (e.g., off-label use, use in combination with another drug or medical device) and from any route of administration, formulation, or dose, including an overdose. An AE can arise from any delivery, implantation, or use of a medical device, including medical device failure, subject characteristics that may impact medical device performance (e.g., anatomical limitations), and therapeutic parameters (e.g., energy applied, sizing, dose release, and anatomic fit) associated with medical device use.

All AEs spontaneously reported by the subject and/or in response to an open question from study personnel or revealed by observation, physical examination or other diagnostic procedures will be recorded in the source document and on the appropriate pages of the CRF. Any clinically relevant deterioration in clinical finding is considered an AE and must be recorded. When possible, signs and symptoms indicating a common underlying pathology will be noted as one comprehensive event.

Documentation regarding the AE will include the nature, date of onset, end date, severity, relationship to IP, action(s) taken, seriousness, and outcome of any sign or symptom observed by the investigator or reported by the subject upon indirect questioning. Exacerbation of conditions related to the signs and symptoms of DED will not be reported as an AE.

### **9.1.1 Severity**

Severity of an AE is defined as a qualitative assessment of the degree of intensity of an AE as determined by the investigator or reported by the subject. The assessment of severity is made irrespective of relationship to the IP or seriousness of the event and will be evaluated according to the following scale:

- ***Mild:*** Event is noticeable to the subject, but is easily tolerated and does not interfere with the subject's daily activities.
- ***Moderate:*** Event is bothersome, possibly requiring additional therapy, and may interfere with the subject's daily activities.
- ***Severe:*** Event is intolerable, necessitates additional therapy or alteration of therapy, and interferes with the subject's daily activities.

### **9.1.2 Relationship to Investigational Product**

The relationship of each AE to the IP will be determined by the investigator using these explanations:

- ***Related:*** A reasonable possibility exists that the IP caused the AE. A related AE can be further defined as follows:
  - Occurs within a reasonable temporal sequence to administration of study drug
  - Cannot be explained by concurrent disease or other drugs or chemicals
  - Improves or disappears on stopping or reducing study drug (de-challenge)
  - Reappears on repeated exposure to study drug (re-challenge)
  - Is an unusual event that is known to be associated with the drug or this class of compound, and cannot be explained by other therapy or the participant's physical condition
  - Unlikely to be attributed to concurrent disease or other drugs or a clinically reasonable response on withdrawal (de-challenge)
- ***Not Related:*** A reasonable possibility does not exist that the IP caused the AE. A not related AE can be further defined as follows:
  - Occurs with a temporal relationship to administration of study drug which makes a causal relationship improbable
  - Other drugs, chemicals or underlying disease provide plausible explanations of causality
  - Is known to be associated with the participant's clinical condition, or with other medication taken by the participant

Suspected adverse reaction means any AE for which there is a reasonable possibility that the IP caused the AE. "Reasonable possibility" means there is evidence to suggest a causal relationship between the IP and the AE. Types of evidence that would suggest a causal relationship between the IP and the AE event include: a single occurrence of an event that is uncommon and known to be strongly associated with IP exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome); one or more occurrences of an event that is not commonly associated with IP exposure, but is otherwise uncommon in the population exposed to the IP (e.g., tendon rupture); an

aggregate analysis of specific events observed in a clinical trial (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy) that indicates those events occur more frequently in the IP-treatment group than in a concurrent or historical control group.

The investigator will initially classify the relatedness of an AE, but the final classification is subject to the Medical Monitor's determination unless revised by the Sponsor, which has the ultimate responsibility for judging relatedness.

### **9.1.3 Expectedness**

The expectedness of an AE should be determined based upon existing safety information about the IP using these explanations:

- ***Unexpected:*** An AE that is not listed in the Investigator's Brochure (IB) or is not listed at the specificity or severity that has been observed.
- ***Expected:*** An AE that is listed in the IB at the specificity and severity that has been observed.
- ***Not applicable:*** An AE unrelated to the IP.

AEs that are mentioned in the IB as occurring with a class of products or as anticipated from the pharmacological/mechanical (or other) properties of the product, but are not specifically mentioned as occurring with the particular product under investigation are to be considered unexpected.

The investigator will initially classify the expectedness of an AE, but the final classification is subject to the Medical Monitor's determination.

## **9.2 Serious Adverse Events**

An AE is considered serious if, in the view of either the investigator or Sponsor, it results in any of the following outcomes:

- Death;
- Is life-threatening;

Note: An AE is considered "life-threatening" if, in the view of either the investigator or sponsor, its occurrence places the subject at immediate risk of death. It does not include an AE that, had it occurred in a more severe form, might have caused death.

- Inpatient hospitalization or prolongation of existing hospitalization;

Note: The term "inpatient hospitalization" refers to any inpatient admission (even if less than 24 hours), unless the inpatient admission was pre-planned prior to the signing of the informed consent. For chronic or long-term inpatients, inpatient admission includes transfer within the hospital to an acute/intensive care inpatient unit. Inpatient hospitalization does not include: emergency room visits; outpatient/same-day/ambulatory procedures; observation/short stay units; rehabilitation facilities; hospice facilities; nursing homes; or clinical research/phase 1 units.

Note: The term "prolongation of existing hospitalization" refers to any extension of an inpatient hospitalization beyond the stay anticipated or

required for the reason for the initial admission as determined by the investigator or treating physician.

- A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;

Note: A serious adverse event (SAE) specifically related to visual threat would be interpreted as any potential impairment or damage to the subject's eyes (e.g., hemorrhage, retinal detachment, central corneal ulcer or damage to the optic nerve).

- A congenital anomaly/birth defect.

Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

### **9.3 Procedures for Reporting Serious Adverse Events**

All SAEs and their outcomes, regardless of causality or expectedness, must be reported to █ and the Sponsor as required by the IRB/Independent Ethics Committee(IEC), federal, state, or local regulations and governing health authorities and recorded on the appropriate CRF. Adverse events will be collected from the time of the signing of the ICF until the follow-up phone call (about 7 days after the final day of randomized study drug treatment).

#### **9.3.1 Reporting a Serious Unexpected Suspected Adverse Reaction**


All SAEs that are both 'suspected' and 'unexpected' are also to be reported to the IRB/IEC and the regulatory authorities as required by the IRB/IEC, federal, state, or local regulations and governing health authorities.

#### **9.3.2 Reporting a Serious Adverse Event**

To ensure subject safety, all SAEs, regardless of relationship to the IP, must be immediately reported. All information relevant to the SAE must be recorded on the appropriate CRFs. The investigator is obligated to pursue and obtain information requested by █ and/or the Sponsor in addition to that information reported on the CRF. All subjects experiencing a SAE must be followed up and the outcome reported.

In the event of a SAE, the investigator will notify █ and the Sponsor immediately using the contact information below; obtain and maintain all pertinent medical records, information, and medical judgments from colleagues who assisted in the treatment and follow-up of the subject; provide █ and the Sponsor a complete case history, which includes a statement as to whether the event was or was not suspected to be related to the use of the IP; and inform the IRB/IEC of the SAE within their guidelines for reporting SAEs.

Contact information for reporting SAEs:



#### **9.4 Procedures for Unmasking (if applicable)**

All subjects, investigators, and study personnel involved with the conduct of the study will be masked with regard to treatment assignments. When medically necessary, the investigator may need to determine what treatment group has been assigned to a subject. When possible (i.e., in non-emergent situations), ■■■ and/or the Sponsor will be notified before unmasking the investigator. ■■■ and/or the Sponsor must be informed immediately about any unmasking event.

If the investigator identifies a medical need that requires unmasking the treatment assignment of a subject, ■■■ and/or the medical monitor will be contacted prior to unmasking the identity of the IP, if possible. ■■■ will ask the staff to complete and send them the Unmasking Request Form. ■■■ will notify the Sponsor and jointly determine if the unmasking request should be granted. In addition, they may consult the medical monitor as needed. The result of the request will be documented on the Unmasking Request Form. If approval is granted to unmask a subject, written permission will be provided on the Unmasking Request Form. The investigator will unmask the subject using the interactive web response system (IWRS), complete the Unmasking Memo form, include it in the subject's study file and make a copy for the trial master file (TMF). For each unmasked request, the reason, date, signature, and name of the person unmasking the subject must be noted in the subject's study file.

Unmasked subjects will be discontinued from the study and followed for safety monitoring, until resolution of the AE or study completion, whichever occurs last.

#### **9.5 Type and Duration of the Follow-up of Subjects after Adverse Events**

The investigator will follow unresolved AEs to resolution until the subject is lost to follow-up, or until the AE is otherwise classified. Resolution means the subject has returned to baseline state of health or the investigator does not expect any further

improvement or worsening of the AE. If the subject is lost to follow-up, the investigator will make 3 reasonable attempts to contact the subject via telephone, USPS, or certified mail. All follow-up will be documented in the subject's source document. Non-serious AEs identified during the last scheduled contact must be recorded on the AE eCRF with the status noted.

If the investigator becomes aware of any new information regarding an existing SAE (i.e., resolution, change in condition, or new treatment), a new SAE/Unanticipated Report Form must be completed and faxed to [REDACTED] within 24 hours of the site's awareness of the new information. The original SAE form is not to be altered. The report will include a description of the event, treatment, and whether it was resolved or continues.

## **10 STATISTICAL HYPOTHESES AND METHODS OF ANALYSES**

### **10.1 Analysis Populations**

The following analysis populations will be considered:

- Intent-to-Treat Population – The intent-to-treat (ITT) population includes all randomized subjects. Subjects in the ITT population will be analyzed as randomized.
- Per-Protocol Population – The per-protocol (PP) population includes subjects in the ITT population who do not have significant protocol deviations and who complete the study. Protocol deviations will be assessed prior to database lock and unmasking. Subjects in the PP population will be analyzed as treated.
- Safety Population – The safety population includes all randomized subjects who have received at least one dose of the investigational product. Subjects in the Safety population will be analyzed as treated.

The statistical analysis of safety data will be performed for the safety population. The analysis of efficacy data will be performed for the ITT population and on the PP population as sensitivity analyses.

### **10.2 Statistical Hypotheses**

The following primary hypotheses will be tested against their respective two-sided alternative hypotheses in the order:

$H_{01}$ : There is no difference in the change from baseline in the post-CAE inferior corneal staining score after 28 days of treatment of [REDACTED] K-161 [REDACTED] compared to vehicle.

$H_{02}$ : There is no difference in the change from baseline in the post-CAE ocular discomfort score after 28 days of treatment of [REDACTED] K-161 [REDACTED] compared to vehicle.

Upon rejecting both  $H_{01}$  and  $H_{02}$ , the secondary hypotheses will be tested as detailed in Section 10.4.4 in the following order

$H_{03}$ : There is no difference in the change from baseline in the pre-CAE Schirmer's test value after 28 days of treatment of [REDACTED] K-161 [REDACTED] compared to vehicle.

$H_{04}$ : There is no difference in the change from baseline in the post-CAE TFBUT after 28 days of treatment of [REDACTED] K-161 [REDACTED] compared to vehicle.

These four hypotheses will be tested hierarchically, each at the alpha = 0.05 level to maintain a study-wise Type I error rate at 0.05.

### **10.3 Sample Size**

This study is expected to enroll 240 subjects in a 1:1:1:1 ratio across four treatment arms, or 60 subjects per treatment arm. In addition, randomization will be stratified such that [REDACTED] will be randomized in each treatment arm.

The standard deviation (SD) for change from baseline in post-CAE inferior corneal fluorescein staining ranges between 0.68 and 0.81 units. Assuming a common SD of 0.77, a sample size of 60 subjects per group will have approximately 90% power to detect a difference of 0.46 units between the active treatment group and the vehicle group using a two-sample t-test at a two-sided significance level of 0.05. Again, it is assumed that adjusting for baseline and site will further reduce variability and provide >90% power.

Likewise, the SD for change from baseline scores in the post-CAE ODS at Day 29 is assumed a common SD of 0.82, a sample size of 60 subjects per group will have approximately 90% power to detect a difference of 0.49 units between the active treatment group and the vehicle group using a two-sample t-test at a two-sided significance level of 0.05. It is assumed that adjusting for baseline and site will further reduce variability and provide >90% power.

### **10.4 Statistical Analysis**

#### **10.4.1 General Considerations**

Quantitative variables will be summarized descriptively using number of subjects (n), mean, SD, median, minimum, and maximum. Qualitative variables will be summarized using counts and percentages.

All summaries will be presented by treatment group. Summaries will be provided for demographics, baseline medical history, concurrent therapies, and subject disposition.

For the purpose of summarization, medical history, concurrent therapies, and AEs will be coded using the MedDRA and WHO drug dictionaries, as appropriate.

Change from pre-CAE to post-CAE will be calculated as post-CAE value minus pre-CAE value. Baseline measures are defined as the last non-missing measure prior to the initiation of randomized study treatment. Change from baseline will be calculated as follow-up visit value minus baseline value. Treatment comparisons between active and vehicle will be calculated as active minus vehicle.

All analyses will be 2-sided at a significance level of 0.05 unless otherwise specified. For all efficacy analyses, 95% confidence intervals on the difference between each dose of K-161 and vehicle will be provided.

#### **10.4.2 Unit of Analysis**

Safety endpoints will be analyzed for both eyes. For efficacy endpoints, the unit of analysis will be the study eye, or the “worst eye,” as defined by the following:

Worst Eye: Eyes are eligible for analysis if they meet all of the inclusion criteria. At least one eye (the right eye or the left eye) must meet all of the criterial. In the case that both eyes are eligible for analysis, the worst eye will be selected as the eye with the worst post-CAE inferior corneal staining at Visit 2. If the post-CAE inferior

corneal staining at Visit 2 is the same in both eyes then the eye with the worst post-CAE ODS at Visit 2 will be worst eye. If the post-CAE inferior corneal staining and ocular discomfort are the same in both eyes then the right eye will be selected as the worst eye.

#### **10.4.3 Missing Data**

Missing data will be imputed using multiple imputation with a control-based pattern mixture model on the ITT population for the primary analyses, the important secondary, other secondary, and exploratory comparisons.

Sensitivity analyses of the primary analyses and important secondary comparisons will include the following in order to provide a robust understanding of the impact of missing and spurious data:

- Using complete case data (i.e. observed data only) on the ITT population
- Using last observation carried forward (LOCF) on the ITT population
- Multiple imputation under missing at random assumption with Markov Chain Monte Carlo (MCMC) techniques on the ITT population
- Using complete case data on the PP population.

No imputation will be used for safety endpoints.

#### **10.4.4 Multiplicity Consideration**

Common factors for multiplicity are multiple arms and multiple endpoints.

##### **1) Multiple arms**

The primary treatment comparison will be between the [REDACTED] K-161 [REDACTED] treatment arm and the vehicle [REDACTED] treatment arm. [REDACTED]  
[REDACTED].

##### **2) Multiple endpoints**

The primary and important secondary endpoints will be tested hierarchically to maintain the study-wise Type I error rate of 0.05. First, change from baseline in inferior corneal fluorescein staining will be tested at an alpha level of 0.05. The test for change from baseline scores in the ODS will be conducted at an alpha level of 0.05 only if the previous test demonstrates significance. The test for change from baseline in Schirmer's test will be conducted at an alpha level of 0.05 only if the previous test demonstrates significance. The test for change from baseline in TFBUT will be conducted at an alpha level of 0.05 only if the previous test demonstrates significance. [REDACTED]  
[REDACTED]

The hierarchical testing order will be as follows:

Primary comparisons:

1. Comparison of the change from baseline in post-CAE inferior corneal staining at Day 29 ([REDACTED] K-161 [REDACTED] vs vehicle)
2. Comparison of the change from baseline in post-CAE ocular discomfort at Day 29 ([REDACTED] K-161 [REDACTED] vs vehicle)

Important Secondary comparisons:

3. Comparison of the change from baseline in pre-CAE Schirmer's test value at Day 29 ([REDACTED] K-161 [REDACTED] vs vehicle)

#### 4. Comparison of the change from baseline in post-CAE TFBUT at Day 29 (K-161 vs vehicle)

Thus, the study-wise Type I error rate will be maintained at 0.05 by considering only one dose of K-161 as the primary treatment comparison and using a hierarchical testing procedure.

#### 10.4.5 Efficacy Analyses

## Primary Efficacy Analyses

The primary comparisons of change from baseline in post-CAE inferior corneal staining and ocular discomfort between the [REDACTED] K-161 [REDACTED] group and the vehicle group at Day 29, will be performed using analysis of covariance (ANCOVA) models. The respective baseline post-CAE score will be included as a covariate in each model and site will be included as a fixed effect. Treatment by baseline and treatment by site interactions will be explored in separate models and, if significant, analyses will be performed by baseline stratification and/or site, respectively, to further examine significant interactions. The primary analyses will use the ITT population.

For the primary endpoints, multiple imputation with MCMC techniques will be used. Imputation will be performed by treatment arm with imputation terms for baseline and Day 29 scores.

## Secondary Efficacy Analyses

Secondary and exploratory endpoints will be analyzed similarly to the primary analyses on the ITT population. Continuous and ordinal variables collected at each visit will be summarized descriptively (n, mean, standard deviation, median, minimum and maximum), and analyzed with ANCOVA models comparing each K-161 group to the vehicle group. All visit-based data will be analyzed by visit and for each timepoint, if applicable, as well as the change from baseline.

Data collected pre- and post-CAE will also be analyzed for the change from pre- to post-CAE within each visit. Data collected during the CAE will also be analyzed using repeated measures models including all of the time points from a CAE exposure. Daily subject diary symptom data will be analyzed using each weekly average score from the diaries, as well as using repeated measures models across the diary collection period.

For the two important secondary endpoints, other secondary, and exploratory endpoints, multiple imputation with MCMC techniques will be used. Imputation will be performed by treatment arm with imputation terms for baseline and Day 29 scores.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

#### 10.4.6 Safety Variables

Adverse events will be coded using the MedDRA dictionary. Frequencies and percentages of subjects with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs causing premature discontinuation will be provided by treatment group. An AE is treatment emergent if it occurs or worsens after the first dose of study treatment. Furthermore, frequencies will be given of subjects with TEAEs by

system organ class; by system organ class and preferred term; by system organ class, preferred term and maximal severity; by system organ class and preferred term for treatment-related TEAEs; and by system organ class, preferred term, and study day of onset. Separate summaries will be performed for ocular and non-ocular AEs.

10.4.7 | [REDACTED]

10.4.8 | [REDACTED]

Other analyses may be conducted and the details will be included in a separate statistical analysis plan.

10.4.9 | [REDACTED]

10.4.10 | [REDACTED]

10.4.11 | [REDACTED]

10.4.11 **Interim Analyses**

There will be no interim analyses in this study.

## **11 COMPLIANCE WITH GOOD CLINICAL PRACTICES, ETHICAL CONSIDERATIONS, AND ADMINISTRATIVE ISSUES**

This study will be conducted in compliance with the protocol, current versions of the FDA Good Clinical Practice (GCP) regulations, the International Council for the Harmonisation of Technical Requirements for Human Use (ICH) GCP guidance, and in general, consistent with the Declaration of Helsinki. In addition, all applicable local, state, and federal requirements relevant to the use of IP will be met.

### **11.1 Protection of Human Subjects**

#### **11.1.1 Subject Informed Consent**

Informed consent/assent must take place before any study specific procedures are initiated. Signed and dated written informed consent must be obtained from each subject and/or from the subject's parent or legal guardian prior to enrollment into the study. The subject must also be given a copy of the signed ICF.

All informed consent forms must be approved for use by the Sponsor and receive approval/favorable opinion from an IRB/IEC prior to their use. If the ICF requires revision (e.g., due to a protocol amendment or significant new safety information), it is the PI's responsibility to ensure that the amended form is reviewed and approved by [REDACTED] prior to submission to the governing IRB/IEC and that it is read, signed and dated by all subjects currently and subsequently enrolled in the study.

If informed consent is taken under special circumstances (oral informed consent), then the procedures to be followed must be determined by [REDACTED] and/or the Sponsor and provided in writing by [REDACTED] and/or the Sponsor prior to the consent process.

#### **11.1.2 Institutional Review Board (IRB) Approval**

This study is to be conducted in accordance with IRB/IEC regulations (e.g., US FDA 21 Code of Federal Regulations Part 56.103). The PI must obtain appropriate IRB/IEC approval before initiating the study and re-approval at least annually.

Only an IRB/IEC approved version of the ICF will be used.

### **11.2 Ethical Conduct of the Study**

This study will be conducted in accordance with the ethical principles that originated with the Declaration of Helsinki.

### **11.3 Subject Confidentiality**

All personal study subject data collected and processed for the purposes of this study will be maintained by the PI and site staff with adequate precautions as to ensure that the confidentiality of the data is in accordance with local, state, and federal laws and regulations.

Monitors, auditors and other authorized representatives of [REDACTED] the Sponsor, the IRB/IEC approving this study, the FDA, the Department of Health and Human Services, other domestic government agencies, and other foreign regulatory agencies will be granted direct access to the subject's original medical and study records for verification of the data and/or clinical study procedures. Access to this information will be permitted to the aforementioned individuals to the extent permitted by law.

A report of the results of this study may be published or sent to the appropriate health authorities in any country in which the IP may ultimately be marketed, but the subject's identity will not be disclosed in these documents.

## **11.4 Documentation**

Source documents may include a subject's medical records, hospital charts, clinic charts, the study subject files, as well as the results of diagnostic tests such as X-rays, laboratory tests, and electrocardiograms. The site's copy of the CRFs serves as the PI's record of a subject's study-related data.

### **11.4.1 Retention of Documentation**

All study related correspondence, subject records, consent forms, record of the distribution and use of all IP, and copies of CRFs must be maintained on file for at least two years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region; or until at least two years have elapsed since the formal discontinuation of clinical development of the IP. These documents will be retained for a longer period if required by the applicable regulatory requirements or by an agreement with the Sponsor. It is the responsibility of the Sponsor to inform the PI when these documents no longer need to be retained.

If the PI retires, relocates, or for other reasons withdraws from the responsibility of keeping study records, the custody of site study data must be transferred to a person who will accept the responsibility. The Sponsor must be notified in writing of the name and address of the new custodian.

## **11.5 Recording of Data on Source Documents and Case Reports Forms (CRFs)**

The PI is responsible for ensuring that study data is completely and accurately recorded on each subject's CRF, source document, and all study-related material. All study data should also be attributable, legible, contemporaneous, accurate, complete, and original. Recorded data must only be corrected in a manner that does not obliterate, destroy, or render illegible the previous entry (e.g., by drawing a single line through the incorrect entry and writing the revision next to the corrected data. The individual correcting the entry must initial and date it.


Data entries for all randomized subjects will use software that conforms to 21 CFR Part 11 requirements, and will be performed only by staff who have access and have been trained on the system. Screen failure data will also be entered in the eCRF. An audit trail will be maintained within the electronic system to capture all changes made within the eCRF database. After the end of the study and database lock, compact discs (CDs) containing copies of all applicable subjects' eCRFs will be provided to each investigator site to be maintained on file by the PI.

## **11.6 Publications**

All data derived from the study will be the property of the Sponsor and must be kept strictly confidential. The investigator must not submit any of the data from this study for publication without prior consent of the Sponsor. The Sponsor will have the final decision regarding any manuscript and publication.

## 12 REFERENCES

- Bron, A. J., C. S. de Paiva, S. K. Chauhan, S. Bonini, E. E. Gabison, S. Jain, E. Knop, M. Markoulli, Y. Ogawa, V. Perez, Y. Uchino, N. Yokoi, D. Zoukhri and D. A. Sullivan (2017). "TFOS DEWS II pathophysiology report." *Ocul Surf* 15(3): 438-510.
- CEQUA (2018). "CEQUA (cyclosporine ophthalmic solution) 0.9% [drug label]. Sun Pharmaceuticals."
- Kudlacz, E., M. Conklyn, C. Andresen, C. Whitney-Pickett and P. Changelian (2008). "The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia." *Eur J Pharmacol* 582(1-3): 154-161.
- Mah, F., M. Milner, S. Yiu, E. Donnenfeld, T. M. Conway and D. A. Hollander (2012). "PERSIST: Physician's Evaluation of Restasis(R) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review." *Clin Ophthalmol* 6: 1971-1976.



Schaumberg, D. A., R. Dana, J. E. Buring and D. A. Sullivan (2009). "Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies." *Arch Ophthalmol* 127(6): 763-768.

Schaumberg, D. A., D. A. Sullivan, J. E. Buring and M. R. Dana (2003). "Prevalence of dry eye syndrome among US women." *Am J Ophthalmol* 136(2): 318-326.

Schaumberg, D. A., D. A. Sullivan and M. R. Dana (2002). "Epidemiology of dry eye syndrome." *Adv Exp Med Biol* 506(Pt B): 989-998.

Stevenson, W., Z. Sadrai, J. Hua, S. Kodati, J. F. Huang, S. K. Chauhan and R. Dana (2014). "Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity." *Cornea* 33(2): 177-183.

Tauber, J., P. Karpecki, R. Latkany, J. Luchs, J. Martel, K. Sall, A. Raychaudhuri, V. Smith, C. P. Semba and O.-. Investigators (2015). "Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study." *Ophthalmology* 122(12): 2423-2431.

## 13 APPENDICES

### APPENDIX 1: SCHEDULE OF VISITS AND MEASUREMENTS

Procedure	Visit 1 Day -14 ± 2		Visit 2 Day 1		Visit 3 Day 8 ± 1	Visit 4 Day 15 ± 2		Visit 5 Day 29 ± 2		Follow-up Phone Call (Day 36 ± 2)
	Pre CAE	Post CAE	Pre CAE	Post CAE		Pre CAE	Post CAE	Pre CAE	Post CAE	
Informed Consent / HIPAA	X									
Medical / Medication History and Demographics	X									
Medical / Medication Update			X		X	X		X		
Adverse Event Query		X	X	X	X	X	X	X	X	X
Ora Calibra® Ocular Discomfort Scale	X	X	X	X	X	X	X	X	X	
Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire	X	X	X	X	X	X	X	X	X	
OSDI® Questionnaire	X		X		X	X		X		
Visual Analog Scale	X	X	X	X	X	X	X	X	X	
Conjunctival Redness	X	X	X	X	X	X	X	X	X	
Tear Osmolarity			X		X	X		X		
TFBUT	X	X	X	X	X	X	X	X	X	
Fluorescein Staining	X	X	X	X	X	X	X	X	X	
Lissamine Green Staining	X	X	X	X	X	X	X	X	X	
Schirmer's Test	X		X		X	X		X		
Blink Rate			X		X	X		X		

Procedure	Visit 1 Day -14 ± 2		Visit 2 Day 1		Visit 3 Day 8 ± 1	Visit 4 Day 15 ± 2		Visit 5 Day 29 ± 2		Follow-up Phone Call (Day 36 ± 2)
	Pre CAE	Post CAE	Pre CAE	Post CAE		Pre CAE	Post CAE	Pre CAE	Post CAE	
Vehicle Run-In Dispensation		X								
Vehicle Run-In Instillation		X								
Vehicle Run-in Collection			X							
Randomization				X						
Study Drug Dispensation				X	X		X			
Study Drug Collection					X	X		X		
Diary Dispensation		X		X	X		X			
Diary Collection			X		X	X		X		
Exit Subject from Study										X
■										
■										
■										
■										

Term	Percentage
Organic	100
Natural	100
Non-GMO	100
Artificial flavoring	100
Artificial coloring	100
Genetically modified organism (GMO)	75
Hydrogenated oil	100
Trans fat	100
Monosodium glutamate (MSG)	100
High-fructose corn syrup	100
Aspartame	100
Artificial sweetener	100
Food additive	100
Food preservative	100
Food coloring	100



1. **What is the primary purpose of the study?** (Please check one box)

11. **What is the primary purpose of the following statement?**

111

1. **What is the primary purpose of the study?** (Please select one)

A solid black horizontal bar, likely a redacted section of a document.

[REDACTED]

1

1

11. **What is the primary purpose of the following statement?**

[REDACTED]


11. **What is the primary purpose of the following statement?**


\_\_\_\_\_

\_\_\_\_\_

11. **What is the primary purpose of the following statement?**

100% 





A large black rectangular redaction box covers the majority of the page content, starting below the header and ending above the footer. The redaction is approximately 1000 pixels wide and 800 pixels high.

Term	Percentage
GMOs	95
Organic	92
Natural	90
Artificial	65
GMOs	95
Organic	92
Natural	90
Artificial	65
GMOs	95
Organic	92
Natural	90
Artificial	65
GMOs	95
Organic	92
Natural	90
Artificial	65

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or [research@uiowa.edu](mailto:research@uiowa.edu).

\_\_\_\_\_

113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or [research@uiowa.edu](mailto:research@uiowa.edu).

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or [research@uiowa.edu](mailto:research@uiowa.edu).

© 2013 Pearson Education, Inc. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part. Due to electronic rights, some third party content may be suppressed from the eBook and/or eChapter(s). Editorial review has determined that any suppressed content does not materially affect the overall learning experience. Pearson Education, Inc. reserves the right to remove additional content at any time if subsequent rights restrictions require it.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or [research@uiowa.edu](mailto:research@uiowa.edu).

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or [research@uiowa.edu](mailto:research@uiowa.edu).

[REDACTED]

10 of 10 pages


For more information, contact the Office of the Vice President for Research and Economic Development at 505-274-3000 or [research@unm.edu](mailto:research@unm.edu).


—  
—  
—

[REDACTED]

[REDACTED]


Digitized by srujanika@gmail.com







[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]





For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or [research@uiowa.edu](mailto:research@uiowa.edu).

---

Digitized by srujanika@gmail.com

10 of 10 pages

[REDACTED]

For more information, contact the Office of the Vice President for Research and the Office of the Vice President for Student Affairs.

10 of 10 | Page

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1151 or [research@uiowa.edu](mailto:research@uiowa.edu).

[REDACTED]

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or [research@iastate.edu](mailto:research@iastate.edu).

© 2013 Pearson Education, Inc.

— 1 —

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or [research@iastate.edu](mailto:research@iastate.edu).

10 of 10 pages

© 2013 Pearson Education, Inc. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part. Due to electronic rights, some third party content may be suppressed from the eBook and/or eChapter(s). Editorial review has determined that any suppressed content does not materially affect the overall learning experience. Pearson Education, Inc. reserves the right to remove additional content at any time if subsequent rights restrictions require it.

© 2006 by the American Psychological Association or American Psychological Association (apa.org)

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or [research@uiowa.edu](mailto:research@uiowa.edu).

Digitized by srujanika@gmail.com

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or [research@iastate.edu](mailto:research@iastate.edu).

[REDACTED]

\_\_\_\_\_

\_\_\_\_\_

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or [research@uiowa.edu](mailto:research@uiowa.edu).

© 2019 Pearson Education, Inc.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or [research@uiowa.edu](mailto:research@uiowa.edu).

[REDACTED]

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or [research@iastate.edu](mailto:research@iastate.edu).

A horizontal bar chart illustrating the distribution of 1000 random numbers. The x-axis represents the value of the random numbers, ranging from 0 to 1. The y-axis represents the frequency of each value, with 100 tick marks. The distribution is approximately uniform, with most values falling between 0.4 and 0.6. The bars are black and have thin white outlines.

Value Range (approx.)	Frequency (approx.)
0.0 - 0.1	10
0.1 - 0.2	10
0.2 - 0.3	10
0.3 - 0.4	10
0.4 - 0.5	100
0.5 - 0.6	100
0.6 - 0.7	100
0.7 - 0.8	100
0.8 - 0.9	100
0.9 - 1.0	10

[REDACTED]

[REDACTED]

[REDACTED]  
[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]  
[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]

[REDACTED]  
[REDACTED]


[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]





### **APPENDIX 3: PROTOCOL AMENDMENT SUMMARY**

Not Applicable.


## APPENDIX 4: SPONSOR AND [REDACTED] APPROVALS

**Protocol Title:** A Phase 2, Prospective, Double-Masked, Randomized, Multi-Center, Vehicle-Controlled, Parallel-group, 4-week Administration Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in non-Japanese/Japanese Adult Subjects with Moderate to Severe Dry Eye Disease Both in Environmental and Controlled Adverse Environmental (CAE) Settings

**Protocol Number:** K-161-2.01US [REDACTED]

**Final Date:** 13June2019

This clinical study protocol was subject to critical review and has been approved by the Sponsor. The following personnel contributed to writing and/or approving this protocol.



## APPENDIX 5: INVESTIGATOR'S SIGNATURE

**Protocol Title:** A Phase 2, Prospective, Double-Masked, Randomized, Multi-Center, Vehicle-Controlled, Parallel-group, 4-week Administration Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in non-Japanese/Japanese Adult Subjects with Moderate to Severe Dry Eye Disease Both in Environmental and Controlled Adverse Environmental (CAE) Settings

**Protocol Number:** K-161-2.01US / [REDACTED]

**Amendment 1 Date:** 13June2019

I agree to implement and conduct the study diligently and in strict compliance with the protocol, Declaration of Helsinki, Health Insurance Portability and Accountability Act, Good Clinical Practice, and all applicable laws and regulations. I agree to maintain all information supplied by [REDACTED] and the Sponsor in confidence and, when this information is submitted to an Institutional Review Board / Independent Ethics Committee or another group, it will be submitted with a designation that it is confidential.

I have read this protocol in its entirety, including the above statement, and I agree to all aspects.

Signed: \_\_\_\_\_

Date: \_\_\_\_\_  
*dd mm yyyy*